Latest Personalized medicine Stories
Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of chemotherapy. The goal of personalized medicine in cancer treatment is to target therapy to the characteristics of the individual tumor. For example Herceptin treatment is of most...
CAMBRIDGE, Mass., May 8, 2012 /PRNewswire/ -- Eutropics Pharmaceuticals today announced that the United States Patent and Trademark Office has issued patent number 8,168,755 entitled, "Antibodies specific to heterodimers of Bcl-2 family and uses thereof." The patent provides a novel method for extending Eutropics' BH3 profiling technology, which is exclusively licensed from the Dana Farber Cancer Institute. This technology assesses the ability of a key part of the cancer cell to...
MASON, Ohio, May 7, 2012 /PRNewswire/ -- AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications. GeneSightRx ADHD analyzes variations in three genes that influence how a...
Scientists hope research is starting point for personalized medicine for women The delicate balance of microbes in the vagina can change drastically over short periods of time in some women, while remaining the same in others, according to a new study led by the University of Maryland School of Medicine's Institute for Genome Sciences and the University of Idaho. The scientists believe that these microbes affect a woman's susceptibility to infection and other diseases, so such changes...
NEW YORK, May 2, 2012 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database The World Anesthesia Drug Market (General, Local, Adjunctive) [http://www.researchmoz.com/the-world-anesthesia-drug-market-general-local-adjunctive-report.html ] The World Anesthesia Drug Market - focuses on three primary segments of anesthesia: - General Anesthesia - Local Anesthesia - Adjunctive Therapies in Anesthesia To Browse Full TOC,...
A team of researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine recently received Department of Defense Breast Cancer Research Program awards to study new therapeutic targets based on the genomic changes that drive tumor formation. The two awards for the partnering principle investigators total $781,455; and were given to BCM young investigator Dr. Xiaosong Wang, assistant professor in the Smith Breast Center, and Dr. Rachel Schiff, associate professor in...
CAMBRIDGE, England and CAMBRIDGE, Mass., April 30, 2012 /PRNewswire/ -- Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, and H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, today announced they have entered into a collaboration agreement to identify and validate a panel of novel cancer drug targets. (Logo:...
Genetic profiling helps find answers to melanoma drug resistance At Moffitt Cancer Center, patients with stage III and IV unresectable melanoma are now routinely genetically profiled for several gene mutations, including the BRAF gene, a known driver oncogene for melanoma. Research has shown that mutations in the BRAF gene determine sensitivity or resistance to a class of drugs that are BRAF inhibitors. "We have found that a large number of patients with melanoma who have the BRAF gene...
GAITHERSBURG, Md., April 25, 2012 /PRNewswire/ -- Zyngenia, Inc., a biopharmaceutical company developing Zybodies(TM), next-generation multi-specific antibody-based drugs in oncology and immunology, announced today that it has appointed David Parkinson, M.D. as a member of its Board of Directors and head of its Clinical Advisory Board. Dr. Parkinson will also serve as Interim Chief Medical Officer (CMO). "Since our start in September 2009, we at Zyngenia have validated our...
AUSTIN, Texas, April 24, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced the expansion of two dedicated groups within its organization: the Life Science and the Biodefense Groups, each with focused initiatives on the development of Luminex technology into these important market segments. While already participating in these markets, further investment in these groups provides additional growth opportunities to build Luminex leadership, advance scientific...
